BeiGene Announces Acceptance of Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia with Breakthrough Therapy Designation

BeiGene announced that the Center for Drug Evaluation of the China National Medical Products Administration has accepted a supplemental new drug application for BeiGene’s BTK inhibitor BRUKINSA as a treatment for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.